OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partnersâ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
æé·äž
åç€Ÿã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 18.67Mã«éããŠããŸãã
é«ãå©çæé·
å瀟ã®çŽå©çã¯æ¥çããªãŒãããŠãããææ°ã®å¹ŽéçŽå©çã¯USD 18.67Mã§ãã
驿£æ°Žæº
åç€Ÿã®ææ°ã®PEã¯-5.29ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé©æ£åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯79.62Mæ ªã§ãåååææ¯ã§29.21%æžå°ããŠããŸãã
ã¹ãã£ãŒãã³ã»ã³ãŒãšã³ãä¿æ
ã¹ã¿ãŒæè³å®¶ã¹ãã£ãŒãã³ã»ã³ãŒãšã³ã¯æ¬éæã9.84Kæ ªä¿æããŠããŸãã
åžå ޿޻åãäœèª¿
å瀟ãžã®æè³å®¶ã®é¢å¿ã¯äœäžããŠããã20æ¥éã®å£²è²·å転çã¯-0.01ã§ãã